Aprea Therapeutics, Inc. (APRE): EBITDA
-$13.21M
Year ended 2025-12-31
-$13.20M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$13.21M | n/m | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | -$14.30M | n/m | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | -$15.46M | n/m | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | -$113.39M | n/m | 2024-03-26, From 2022-01-01 |
| 2021-12-31 | -$37.43M | n/a | 2024-03-26, From 2021-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | -$13.21M | n/m |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | -$22.77M | n/m |
| Lipocine Inc. (LPCN) | 2025-12-31 | -$10.31M | n/m |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | -$3.14M | n/m |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$18.06M | n/m |
| Exicure, Inc. (XCUR) | 2025-12-31 | -$3.99M | n/m |
| CytoDyn Inc. (CYDY) | 2026-05-31 | -$38.56M | n/m |
| Allarity Therapeutics, Inc. (ALLR) | 2024-12-31 | -$27.23M | n/m |
| Lite Strategy, Inc. (LITS) | 2025-06-30 | -$17.09M | n/m |
Compare APRE, CLRB, LPCN, IBO side by side · Screen every company in Pharmaceutical Preparations ↗